183 related articles for article (PubMed ID: 34386763)
1. Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study.
Skertich NJ; Chu F; Tarhoni IA; Szajek S; Borgia JA; Madonna MB
Surg Open Sci; 2021 Oct; 6():10-14. PubMed ID: 34386763
[TBL] [Abstract][Full Text] [Related]
2. Expression of Immunomodulatory Checkpoint Molecules in Drug-Resistant Neuroblastoma: An Exploratory Study.
Skertich NJ; Chu F; Tarhoni IAM; Szajek S; Borgia JA; Madonna MB
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35159017
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma.
Takeuchi M; Miyoshi H; Nakashima K; Kawamoto K; Yamada K; Yanagida E; Muta H; Moritsubo M; Umeno T; Suzuki T; Seto M; Ohshima K
Ann Hematol; 2020 May; 99(5):1093-1098. PubMed ID: 32157421
[TBL] [Abstract][Full Text] [Related]
4. Soluble type immune checkpoint regulators using multiplex luminex immunoassay in chronic hepatitis B patients.
Fadriquela A; Kim CS; Lee KJ; Kang SH; Kim MY; Lee JH
J Clin Pathol; 2021 Dec; 74(12):780-786. PubMed ID: 34016716
[TBL] [Abstract][Full Text] [Related]
5. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
Gonzalez LC; Loyet KM; Calemine-Fenaux J; Chauhan V; Wranik B; Ouyang W; Eaton DL
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1116-21. PubMed ID: 15647361
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 is expressed on human activated naive effector CD4+ T cells. Regulation by dendritic cells and regulatory CD4+ T cells.
Mazerolles F; Rieux-Laucat F
PLoS One; 2021; 16(11):e0260206. PubMed ID: 34793567
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3.
Rapoport BL; Steel HC; Benn CA; Nayler S; Smit T; Heyman L; Theron AJ; Hlatshwayo N; Kwofie LLI; Meyer PWA; Anderson R
Front Oncol; 2023; 13():1097309. PubMed ID: 37064132
[TBL] [Abstract][Full Text] [Related]
8. Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma.
Imai Y; Hasegawa K; Matsushita H; Fujieda N; Sato S; Miyagi E; Kakimi K; Fujiwara K
Oncol Lett; 2018 May; 15(5):6457-6468. PubMed ID: 29616115
[TBL] [Abstract][Full Text] [Related]
9. Clinical Insights Into Novel Immune Checkpoint Inhibitors.
Lee JB; Ha SJ; Kim HR
Front Pharmacol; 2021; 12():681320. PubMed ID: 34025438
[TBL] [Abstract][Full Text] [Related]
10. Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia.
Kang SH; Hwang HJ; Yoo JW; Kim H; Choi ES; Hwang SH; Cho YU; Jang S; Park CJ; Im HJ; Seo JJ; Kim N; Koh KN
Anticancer Res; 2019 Oct; 39(10):5531-5539. PubMed ID: 31570447
[TBL] [Abstract][Full Text] [Related]
11. Emerging Targets of Immunotherapy in Gynecologic Cancer.
Cheng H; Zong L; Kong Y; Gu Y; Yang J; Xiang Y
Onco Targets Ther; 2020; 13():11869-11882. PubMed ID: 33239889
[TBL] [Abstract][Full Text] [Related]
12. Targeting T cell costimulation in autoimmune disease.
Stuart RW; Racke MK
Expert Opin Ther Targets; 2002 Jun; 6(3):275-89. PubMed ID: 12223069
[TBL] [Abstract][Full Text] [Related]
13. Various checkpoint molecules, and tumor-infiltrating lymphocytes in common pediatric solid tumors: Possibilities for novel immunotherapy.
Mochizuki K; Kawana S; Yamada S; Muramatsu M; Sano H; Kobayashi S; Ohara Y; Takahashi N; Hakozaki M; Yamada H; Hashimoto Y; Kikuta A
Pediatr Hematol Oncol; 2019 Feb; 36(1):17-27. PubMed ID: 30870043
[TBL] [Abstract][Full Text] [Related]
14. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
[TBL] [Abstract][Full Text] [Related]
15. Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1
Del Rio ML; de Juan CY; Roncador G; Caleiras E; Álvarez-Esteban R; Pérez-Simón JA; Rodriguez-Barbosa JI
Front Immunol; 2023; 14():1113858. PubMed ID: 37033927
[TBL] [Abstract][Full Text] [Related]
16. Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma.
Sheng QJ; Tian WY; Dou XG; Zhang C; Li YW; Han C; Fan YX; Lai PP; Ding Y
World J Gastrointest Oncol; 2020 Nov; 12(11):1255-1271. PubMed ID: 33250959
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells.
Tao R; Wang L; Murphy KM; Fraser CC; Hancock WW
J Immunol; 2008 May; 180(10):6649-55. PubMed ID: 18453584
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts.
Tao R; Wang L; Han R; Wang T; Ye Q; Honjo T; Murphy TL; Murphy KM; Hancock WW
J Immunol; 2005 Nov; 175(9):5774-82. PubMed ID: 16237069
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoints as potential theragnostic biomarkers for epithelial ovarian cancer.
Habel A; Weili X; Hadj Ahmed M; Stayoussef M; Bouaziz H; Ayadi M; Mezlini A; Larbi A; Yaacoubi-Loueslati B
Int J Biol Markers; 2023 Dec; 38(3-4):203-213. PubMed ID: 37518940
[TBL] [Abstract][Full Text] [Related]
20. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
